公开(公告)号：EP4320105A1

公开(公告)日：2024-02-14

申请号：EP22785326.4

申请日：2022-04-05

申请人： Epiodyne, Inc.

发明人： MEDINA, Julio Cesar ,  NERURKAR, Alok ,  SADLOWSKI, Corinne ,  SEIDL, Frederick ,  CHENG, Heng ,  DUQUETTE, Jason ,  LEE, John ,  HOLAN, Martin ,  DING, Pingyu ,  WANG, Xiaodong ,  WIDJAJA, Tien ,  NGUYEN, Thomas ,  BHATT, Ulhas ,  LI, Yihong ,  WEI, Zhi-liang

IPC分类号： C07D277/22 ,  C07D239/26 ,  C07D213/24 ,  C07D307/38 ,  C07D333/06 ,  C07C237/30 ,  C07C237/20 ,  A61P25/00

公开(公告)号：EP4008717A2

公开(公告)日：2022-06-08

申请号：EP21211967.1

申请日：2021-12-02

申请人： Martin-Luther-Universität Halle-Wittenberg

发明人： HÜTTELMAIER, Stefan ,  MÜLLER, Simon ,  BLEY, Nadine ,  DAILEN, Garcia Martinez ,  SIPPL, Wolfgang ,  GHAZY, Ehab

IPC分类号： C07D333/28 ,  C07D333/38 ,  C07D239/91 ,  C07D495/04 ,  C07D417/12 ,  C07D409/06 ,  C07C237/42 ,  C07C237/30 ,  C07C233/00 ,  C07D295/15 ,  C07D333/78 ,  C07D333/68 ,  C07D409/12 ,  A61P35/00 ,  A61K31/381 ,  A61K31/517 ,  A61K31/519 ,  A61K31/495

摘要： The presented invention provides compounds of formula (I) and (VIII),


or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R 1 , R 2 , W, X, Y, Z, m, n and o are as defined herein. Said compounds of formula (I) are inhibitors of insulin-like growth factor 2 mRNA binding proteins (IGF2BP). Provided are novel inhibitors of IGF2BPs and processes for manufacturing the same. Efficacy of the new compounds is shown in solid cancer models.

公开(公告)号：EP3619193A1

公开(公告)日：2020-03-11

申请号：EP18793826.1

申请日：2018-05-04

申请人： Hepanova, Inc.

发明人： LI, Ke ,  WANG, Belle Xiaohong ,  LI, Yongmei ,  LI, Qiong

IPC分类号： C07C237/30 ,  C07C237/42 ,  C07C311/39

公开(公告)号：EP3438087A1

公开(公告)日：2019-02-06

申请号：EP18151119.7

申请日：2013-04-05

申请人： Boehringer Ingelheim International GmbH

发明人： DEODHAR, Mandar ,  FINDLAY, Alison Dorothy ,  FOOT, Jonathan Stuart ,  JAROLIMEK, Wolfgang ,  MCDONALD, Ian Alexander ,  ROBERTSON, Alan ,  TURNER, Craig Ivan

IPC分类号： C07C235/46 ,  C07C237/30 ,  C07C311/29 ,  C07C323/62 ,  A61K31/18 ,  A61K31/166 ,  A61P29/00

摘要： The application relates to substituted 3-haloallylamine derivatives of Formula I which act as SSAO/VAP-1 inhibitors. The compounds of Formula I, or pharmaceutically acceptable salts thereof, are useful for the treatment of inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.

公开(公告)号：EP3329775A1

公开(公告)日：2018-06-06

申请号：EP18153287.0

申请日：2011-02-24

申请人： Medivation Prostate Therapeutics LLC

发明人： THOMPSON, Andrew ,  LAMBERSON, Carol ,  GREENFIELD, Scott ,  JAIN, Rajendra Parasmal ,  ANGELAUD, Remy

IPC分类号： A01N43/50 ,  A61K31/415 ,  C07D233/86 ,  C07D235/02 ,  C07C237/30

CPC分类号： C07D233/86 ,  C07C231/12 ,  C07C237/30 ,  C07D235/02

摘要： Processes are provided for the synthesis of diarylthiohydantoin and diarylhydantoin compounds, such as compounds of the formula:

wherein X, Y 1 , Y 2 , R 1 , and R 2 are as defined herein. Medicinal products containing the same find particular use in treating prostate cancer, including castration-resistant prostate cancer and/or hormone-sensitive prostate cancer.

公开(公告)号：EP3043790A4

公开(公告)日：2017-08-30

申请号：EP14843462

申请日：2014-09-11

申请人： THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND ,  DUQUESNE UNIV OF THE HOLY GHOST

发明人： CHAKRABARTY SURAVI ,  FLAHERTY PATRICK T ,  MONLISH DARLENE ,  CAVANAUGH JANE E ,  BUROW MATTHEW E ,  ELLIOTT STEVEN ,  HOANG VAN T

IPC分类号： A61K31/245 ,  C07C63/06 ,  C07C69/78 ,  C07C211/55 ,  C07C229/58 ,  C07C237/30 ,  C07C237/32 ,  C07C237/34 ,  C07C237/36 ,  C07D295/16

CPC分类号： C07D295/16 ,  C07C229/58 ,  C07C237/30 ,  C07C237/32 ,  C07C237/34 ,  C07C237/36

公开(公告)号：EP2903965B1

公开(公告)日：2017-03-01

申请号：EP13779617.3

申请日：2013-09-30

申请人： Orion Corporation

发明人： ARVELA, Riina ,  HEIKKINEN, Terhi ,  HOLM, Patrik ,  PRUSIS, Peteris ,  ROSLUND, Mattias ,  SALO, Harri

IPC分类号： C07C237/30 ,  C07C237/44 ,  C07C255/58 ,  C07C323/63 ,  C07D209/08 ,  C07D213/81 ,  C07D213/82 ,  C07D215/48 ,  C07D239/42 ,  C07D317/58 ,  C07D319/18 ,  C07D333/38 ,  C07D405/12 ,  C07D417/12 ,  A61K31/166

CPC分类号： C07D213/82 ,  A61K31/166 ,  A61K31/277 ,  A61K31/357 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/455 ,  A61K31/472 ,  A61K31/505 ,  A61K31/5377 ,  C07C237/30 ,  C07C237/44 ,  C07C255/58 ,  C07C255/60 ,  C07C323/63 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14 ,  C07D209/08 ,  C07D213/81 ,  C07D215/48 ,  C07D217/02 ,  C07D239/42 ,  C07D317/58 ,  C07D319/18 ,  C07D333/38 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

公开(公告)号：EP2907802A4

公开(公告)日：2016-04-20

申请号：EP13845823

申请日：2013-10-11

申请人： TAKEDA PHARMACEUTICAL

发明人： TOMITA NAOKI ,  TOMITA DAISUKE ,  TOMINARI YUSUKE ,  IMAMURA SHINICHI ,  MORIMOTO SHINJI ,  KOJIMA TAKUTO ,  TOYOFUKU MASASHI ,  HATTORI YASUSHI ,  KAKU TOMOHIRO ,  ITO MITSUHIRO

IPC分类号： C07C237/40 ,  A61K31/166 ,  A61K31/167 ,  A61K31/415 ,  A61K31/4453 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  A61P43/00 ,  C07C237/30 ,  C07C237/38 ,  C07D231/40 ,  C07D295/18 ,  C12N9/99 ,  C12N15/09

CPC分类号： C07D487/04 ,  A61K45/06 ,  C07C237/30 ,  C07C237/38 ,  C07C237/40 ,  C07C255/29 ,  C07C255/58 ,  C07C255/60 ,  C07C317/40 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07D207/12 ,  C07D207/46 ,  C07D211/58 ,  C07D213/36 ,  C07D213/40 ,  C07D223/12 ,  C07D231/38 ,  C07D231/40 ,  C07D241/12 ,  C07D241/18 ,  C07D261/14 ,  C07D265/36 ,  C07D277/38 ,  C07D285/135 ,  C07D295/135 ,  C07D309/14 ,  C07D319/18 ,  C07D333/20 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D513/04

摘要： The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R 1 , R 2 and R 3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R 1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R 2 and R 3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.

公开(公告)号：EP2785178A4

公开(公告)日：2015-09-30

申请号：EP12852566

申请日：2012-11-29

申请人： BIKAM PHARMACEUTICALS INC

发明人： QUACH TAN ,  BERMAN JUDD ,  GARVEY DAVID S

IPC分类号： C07C255/54 ,  A61K31/137 ,  A61P27/02 ,  C07C33/50 ,  C07C43/215 ,  C07C43/225 ,  C07C211/45 ,  C07C211/52 ,  C07C217/84 ,  C07C237/30 ,  C07C255/58 ,  C07C323/09 ,  C07D317/46 ,  C07D317/64 ,  C07D317/66

CPC分类号： C07C211/52 ,  C07C33/50 ,  C07C43/215 ,  C07C43/225 ,  C07C49/237 ,  C07C49/813 ,  C07C211/45 ,  C07C211/46 ,  C07C217/84 ,  C07C237/30 ,  C07C255/54 ,  C07C255/58 ,  C07C255/59 ,  C07C323/09 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07D317/46 ,  C07D317/64 ,  C07D317/66

摘要： Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.

公开(公告)号：EP2903965A1

公开(公告)日：2015-08-12

申请号：EP13779617.3

申请日：2013-09-30

申请人： Orion Corporation

发明人： ARVELA, Riina ,  HEIKKINEN, Terhi ,  HOLM, Patrik ,  PRUSIS, Peteris ,  ROSLUND, Mattias ,  SALO, Harri

IPC分类号： C07C237/30 ,  C07C237/44 ,  C07C255/58 ,  C07C323/63 ,  C07D209/08 ,  C07D213/81 ,  C07D213/82 ,  C07D215/48 ,  C07D239/42 ,  C07D317/58 ,  C07D319/18 ,  C07D333/38 ,  C07D405/12 ,  C07D417/12 ,  A61K31/166

CPC分类号： C07D213/82 ,  A61K31/166 ,  A61K31/277 ,  A61K31/357 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/455 ,  A61K31/472 ,  A61K31/505 ,  A61K31/5377 ,  C07C237/30 ,  C07C237/44 ,  C07C255/58 ,  C07C255/60 ,  C07C323/63 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/14 ,  C07D209/08 ,  C07D213/81 ,  C07D215/48 ,  C07D217/02 ,  C07D239/42 ,  C07D317/58 ,  C07D319/18 ,  C07D333/38 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

摘要： Compounds of formula I, wherein A, B, X, Z and R
1 -R
6 , are as defined in the claims, exhibit TRPA 1 activity and are thus useful as TRPA1 modulators.

摘要翻译： 式I的化合物，其中A，B，X，Z和R 1 -R 6如权利要求中所定义，表现出TRPA1活性，因此可用作TRPA1调节剂。